


**Nearly half of every dollar spent  
on medicines goes to someone  
who doesn't make them.**

**A new analysis from the Berkeley Research Group reaffirms the need to look at the entire supply chain in order to solve patient affordability challenges.**

Here are three key findings from the report:

**1**


Hospitals, health insurers, pharmacy benefit managers, the government and others got nearly 50% of what was spent on brand medicines in 2018, up from 33% five years prior.



2

Between 2015 and 2018, the amount innovative biopharmaceutical companies retained from the sale of brand medicines increased, on average, 2.6% annually, in line with inflation.

### Total Brand Medicine Spending (\$B), 2015-2018




#### Other Stakeholders:

-Health plans -Government -Hospitals -Other supply chain entities

3

The amount hospitals, pharmacies and other health care providers retained on the sale of brand medicines nearly doubled between 2013 and 2018, increasing from \$24.7 billion to \$48.6 billion.



**Policymakers can't help patients afford their medicine if they ignore where almost half the money is going.**